Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  topotecan hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-C-004-14, NCI-2015-01497, NCT02421588
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-331, NCI-2015-01362, 2015-001097-18, NCT02481830
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0861, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, 8329, NCT01012817
Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-03, NCI-2015-01365, NCT02514447
ATR Kinase Inhibitor VX-970 and Topotecan Hydrochloride in Treating Patients with Previously Treated Lung, Ovarian, Cervical, or Neuroendocrine Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0150, NCI-2015-01398, 346215, P142115, NCT02487095
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ALDOXORUBICIN-P2-SCLC-01, NCI-2014-02472, NCT02200757
Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1463, NCI-2014-02399, Mod14-002986-03, NCT02312245
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Stage IVB or Recurrent Cervical Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0625, NCI-2015-00211, NCT02348398
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1365, NCI-2015-00133, NCT02364713
Effect of Acetylcysteine with Topotecan Hydrochloride on the Tumor Microenvironment in Patients with Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15P.404, NCI-2015-01564, 2015-005, 2405, JeffTrial 7408, NCT02569957
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 508-08, NCI-2009-01308, UNMC-50808, IRB #508-08, NCT00856037
Crizotinib and Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 21 years
Trial IDs: ADVL1212, NCI-2012-01968, CDR0000734059, COG-ADVL1212, NCT01606878
Sirolimus, Cyclophosphamide, and Topotecan Hydrochloride in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: CC# 12083, NCI-2012-01942, NCT01670175
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 29
Trial IDs: N2012-01, NCI-2015-00641, P01CA081403, NCT02030964
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Under 30
Trial IDs: NANT 2013-02, NCI-2015-00984, NCT02298348
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0640, NCI-2015-00693, NCT02419495
Risk-Adapted Therapy in Treating Young Children with Brain Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3 at diagnosis
Trial IDs: SJYC07, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Start Over